Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
DURHAM, N.C., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) , a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth ...
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - Bioventus ( NASDAQ:BVS )
DURHAM, N.C., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. BVS, a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on ...
Bioventus ( BVS ) Misses Q2 Earnings and Revenue Estimates
Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
DURHAM, N.C., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement ( the "Credit Agreement" ) consisting of ...
Bioventus Receives FDA 510 ( k ) Clearances for two Next-Generation Peripheral Nerve Stimulation Products - Bioventus ( NASDAQ:BVS )
DURHAM, N.C., July 30, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. BVS, a global leader in innovations for active healing, announced today a significant milestone with the U.S.
Bioventus Receives FDA 510 ( k ) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
DURHAM, N.C., July 30, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) , a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration ( FDA ) 510 ( k ) clearances for both TalisMann™ and StimTrial™, expanding the ...
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
DURHAM, N.C., July 29, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on ...
Do Options Traders Know Something About Bioventus Stock We Don't?
Investors need to pay close attention to Bioventus stock based on the movements in the options market lately.
Bioventus ( BVS ) Q1 Earnings and Revenues Surpass Estimates
Bioventus (BVS) delivered earnings and revenue surprises of 33.33% and 2.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Ensign Group Invests in Growth With New Facility Acquisitions
ENSG continues its strategic growth with new acquisitions across Washington and California.
Here's Why Bioventus ( BVS ) Is a Great 'Buy the Bottom' Stock Now
Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Centene & HMHB Hawaii Expand Partnership for Maternal Care
CNC's Ohana Health Plan and HMHB Hawaii expand maternal care, enhancing support for mothers and babies through strategic investment and community partnerships.
Centene's Meridian Unit Secures a D-SNP Contract in Illinois
CNC's Meridian Health Plan wins a D-SNP contract in Illinois, expanding enhanced managed care for Medicare-Medicaid-eligible individuals. The deal is likely to boost Centene's foothold and membership base in the state.
Bioventus ( BVS ) Upgraded to Buy: Here's What You Should Know
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million - Bioventus ( NASDAQ:BVS )
Bioventus Q4 adjusted EPS rose to $0.15 from $0.07, surpassing the $0.08 consensus. Sales grew 13.5% to $153.6 million. Pain treatment sales climbed 18.7% to $62.8M, while Surgical Solutions rose 16.8% to $46.43M. Restorative Therapies dipped 0.6% to $25.95M.
Bioventus ( BVS ) Q4 Earnings and Revenues Surpass Estimates
Bioventus (BVS) delivered earnings and revenue surprises of 66.67% and 5.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
DURHAM, N.C., March 11, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial ...
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
DURHAM, N.C., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on ...
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 - Bioventus ( NASDAQ:BVS )
DURHAM, N.C., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. BVS ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, ...
USANA Health Sciences ( USNA ) Surpasses Q4 Earnings and Revenue Estimates
USANA Health (USNA) delivered earnings and revenue surprises of 30.61% and 2.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals ( RXRX ) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
DURHAM, N.C., Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners ( ...
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - Bioventus ( NASDAQ:BVS )
DURHAM, N.C., Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc.
Is Bioventus ( BVS ) Outperforming Other Medical Stocks This Year?
Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Wall Street Analysts Think Bioventus ( BVS ) Could Surge 26.03%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings - Yum Brands ( NYSE:YUM )
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Tuesday. The Dow traded up 0.96% to 42,197.88 while the NASDAQ rose 1.26% to 18,408.47. The S&P 500 also rose, gaining, 1.03% to 5,771.80. Consumer discretionary shares surged by 1.8% on Tuesday.
S&P 500 Gains 1%; Vimeo Shares Spike Higher - Vimeo ( NASDAQ:VMEO )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Tuesday. The Dow traded up 0.86% to 42,154.69 while the NASDAQ rose 1.25% to 18,407.20. The S&P 500 also rose, gaining, 1.01% to 5,770.63. Consumer discretionary shares surged by 1.7% on ...
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Verrica Pharmaceuticals ( NASDAQ:VRCA )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.22% to 41,887.70 while the NASDAQ rose 0.70% to 18,307.76. The S&P 500 also rose, gaining, 0.50% to 5,741.41.
Bioventus ( BVS ) Matches Q3 Earnings Estimates
Bioventus (BVS) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Bioventus ( BVS ) This Year?
Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 - Bioventus ( NASDAQ:BVS )
DURHAM, N.C., Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Bioventus Inc. BVS ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November ...
Bioventus Surges 73% in Three Months: Time to Buy the Stock?
BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.
Are Medical Stocks Lagging ChromaDex ( CDXC ) This Year?
Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.
Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.
Here's Why Investors Should Consider Buying Corcept Stock Now
Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.
Beat the Market Like Zacks: Talen Energy, CBRE, 3M in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
First September Gains in 5 Years? Buy 3 Breakout Stocks Now - Axogen ( NASDAQ:AXGN ) , Bioventus ( NASDAQ:BVS )
September has always been the worst month for the stock market. In early September, stocks gyrated as investors were concerned about a cooling U.S. economy. However, things have begun to improve following the Federal Reserve's half-point interest rate cut that restored faith in economic strength.
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
Longboard Stock Soars on FDA Designations for Epilepsy Drug
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
